GenoScreen
Metabiote® protocol is now GCLP compliant
Metabiote®, the reference protocol in targeted metagenomics developed by GenoScreen, is now GCLP compliant.
A major advance in the fight against multidrug-resistant tuberculosis
Deeplex®-MycTB, was used in a study published in The Lancet Infectious Diseases highlighting the spread of tuberculosis strains resistant to first-line antibiotics, not detected by current diagnostic tests.
Discover Deeplex-MycTB
Discover Deeplex-MycTB, a next-generation molecular analysis solution that allows, in a single test,
- to identify the mycobacteria of the M. tuberculosis complex causing tuberculosis,
- to predict their resistance to multiple antibiotics of first and second intent
- and to type them for epidemiological surveillance purposes.
December 3-4, 2024
Adebiotech - Innovations to fight respriatory diseases, Paris-Romainville - France
More informationSubcategories
Partners
GenoScreen develops its technologies and know-how in genomics within a dense, well-structured network of partners.
These collaborations co-fund ambitious research programs and jointly develop innovative technologies: an effective and agile strategy that opens up new opportunities for our staff.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.